JANSSEN RESEARCH & DEVELOPMENT, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis

Phase 3

Active, not recruiting

Conditions: Colitis, Ulcerative

Interventions: Drug: Golimumab
Drug: Infliximab

First Posted Date: 2018-07-24

Last Posted Date: 2025-05-25

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 84

Registration Number: NCT03596645

Locations: 🇵🇱
Szpital Uniwersytecki NR 1 IM Dr Antoniego Jurasza, Bydgoszcz, Poland
🇵🇱
Wojewodzki Specjalistyczny Szpital Dzieciecy im Prof Stanislawa Popowskiego, Olsztyn, Poland
🇵🇱
Centrum Zdrowia Matki Dziecka i Mlodziezy, Warszawa, Poland

and more 55 locations

A Study to Assess the Effect of Ritonavir on the Single-Dose Pharmacokinetics of JNJ-61393215 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: JNJ-61393215
Drug: Ritonavir

First Posted Date: 2018-07-20

Last Posted Date: 2025-04-27

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 12

Registration Number: NCT03593954

Locations: 🇺🇸
PRA International, Salt Lake City, Utah, United States

A Study of JNJ-64565111 After Single Subcutaneous Administration at Different Injection Sites in Otherwise Healthy Overweight/Obese Adult Participants and a Study of JNJ-6456511 in Otherwise Healthy Obese Adult Participants After Multiple Dose

Phase 1

Completed

Conditions: Obesity

Interventions: Drug: JNJ-64565111

First Posted Date: 2018-07-16

Last Posted Date: 2019-04-16

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 52

Registration Number: NCT03586843

Locations: 🇺🇸
Celerion, Tempe, Arizona, United States

A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Erdafitinib

Phase 1

Terminated

Conditions: Hepatic Impairment

Interventions: Drug: Erdafitinib

First Posted Date: 2018-07-16

Last Posted Date: 2025-02-03

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 26

Registration Number: NCT03587363

Locations: 🇩🇪
CRS Clinical Research Services Kiel GmbH, Kiel, Germany
🇩🇪
APEX GmbH, Munchen, Germany

Characterization of T-Cell Response in Participants Previously Treated With JNJ-54861911 (Atabecestat)

Early Phase 1

Completed

Conditions: Alzheimer Disease

Interventions: Drug: Atabecestat

First Posted Date: 2018-07-16

Last Posted Date: 2025-04-27

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 9

Registration Number: NCT03587376

Locations: 🇧🇪
Ziekenhuis Hoge Beuken, Hoboken, Belgium
🇫🇷
Hôpital Fernand Widal, Paris, France
🇩🇪
CTC North GmbH & Co. KG, Hamburg, Germany

and more 2 locations

A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Severely Obese Participants With Type 2 Diabetes Mellitus

Phase 2

Completed

Conditions: Obesity and Diabetes Mellitus, Type 2

Interventions: Drug: JNJ-64565111 Dose Level 2
Drug: JNJ-64565111 Dose Level 1
Drug: JNJ-64565111 Dose Level 3
Drug: Placebo

First Posted Date: 2018-07-16

Last Posted Date: 2020-01-07

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 196

Registration Number: NCT03586830

Locations: 🇺🇸
Prestige Clinical Research, Franklin, Ohio, United States
🇺🇸
Central Research Associates, Inc., Birmingham, Alabama, United States
🇺🇸
Premeir Clinical Research Institute, Miami, Florida, United States

and more 24 locations

AAVCAGsCD59 for the Treatment of Wet AMD

Phase 1

Completed

Conditions: Wet Age-related Macular Degeneration

Interventions: Drug: Intravitreal anti-VEGF
Biological: Intravitreal AAVCAGsCD59
Drug: Oral prednisolone

First Posted Date: 2018-07-13

Last Posted Date: 2025-03-30

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 25

Registration Number: NCT03585556

Locations: 🇺🇸
Vitreo-Retina Associates, Worcester, Massachusetts, United States
🇺🇸
Ophthalmic Consultants of Boston, Boston, Massachusetts, United States

A Study to Investigate the Whole Body Distribution and Radiation Dosimetry of the Positron Emission Tomography Ligand Fluoride-18 (18F)-JNJ-64326067 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: 18F-JNJ-64326067

First Posted Date: 2018-07-10

Last Posted Date: 2025-04-27

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 6

Registration Number: NCT03581916

Locations: 🇺🇸
Invicro, New Haven, Connecticut, United States

A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS

Phase 1

Active, not recruiting

Conditions: Solid Tumor, Adult
Neoplasms
Myelodysplastic Syndromes
Non-Hodgkin Lymphoma

Interventions: Drug: JNJ-64619178

First Posted Date: 2018-06-29

Last Posted Date: 2025-05-04

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 114

Registration Number: NCT03573310

Locations: 🇨🇦
Princess Margaret Cancer Centre University Health Network, Toronto, Ontario, Canada
🇺🇸
Florida Specialist and Cancer Institute, Sarasota, Florida, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 15 locations

A Single and Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of JNJ-42165279 in Healthy Japanese Male Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: JNJ-42165279
Drug: Placebo

First Posted Date: 2018-06-20

Last Posted Date: 2025-04-27

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 12

Registration Number: NCT03564379

Locations: 🇺🇸
WCCT Global, LLC, Cypress, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy